Seymour said the Government had, in 2024, allocated Pharmac its largest-ever budget of $6.294 billion over four years, plus a ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

The estimated global incidence of AL amyloidosis was one in 95,800 people. New Zealand data was not recorded, he said. Pharmac director of pharmaceuticals Geraldine MacGibbon said it understood the ...

Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at ...

He leads the Multiple Myeloma and Amyloidosis Multidisciplinary Team and Research Program. With over 25 years of experience in clinical and translational research, Dr. Zonder has had the ...

At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.

He leads the Multiple Myeloma and Amyloidosis Multidisciplinary Team and Research Program. With over 25 years of experience in clinical and translational research, Dr. Zonder has had the privilege of ...

One was “multiple myeloma,” the rare cancer she didn ... center for almost 80 years before it closed. “I have kidney amyloidosis, and I have Waldenström's Macroglobulinemia,” said ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...